News
06-18-2025, 10:00 AM
The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.
More... (https://www.news-medical.net/news/20250618/New-switchable-CAR-T-therapy-enters-phase-1-trial-for-advanced-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20250618/New-switchable-CAR-T-therapy-enters-phase-1-trial-for-advanced-breast-cancer.aspx)